Diagnostic beta-amyloid 42 (Aβ42) antibodies (anti-beta-amyloid 42, anti-Aβ42) and antigens (recombinant beta-amyloid 42 (Aβ42) protein) for Neurodegenerative diseases Aβ42 detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Cat:GMP-h-Aβ42
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Genemedi produces core diagnostic ingredients for test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome. GeneMedi offers paired diagnostics grade beta-amyloid 42 (Aβ42) antibodies (monoclonal antibody, mab) and antigens for Neurodegenerative diseases (Alzheimer Disease(AD)) rapid test kit of beta-amyloid 42 (Aβ42) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Neurodegenerative diseases (Alzheimer Disease(AD) ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.
Genemedi produces core diagnostic ingredients for test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome. GeneMedi offers paired diagnostics grade beta-amyloid 42 (Aβ42) antibodies (monoclonal antibody, mab) and antigens for Neurodegenerative diseases (Alzheimer Disease(AD)) rapid test kit of beta-amyloid 42 (Aβ42) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Neurodegenerative diseases (Alzheimer Disease(AD) ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.Easily accessible biomarkers are needed for the early identification of individuals at risk of developing Alzheimer’s disease (AD) in large population screening strategies. Low plasma Aβ42/40 was associated with more pronounced decline in cognitive function (measured by multiple outcomes) over time. Findings suggest that plasma Aβ42/40 may be used to identify people at risk of cognitive decline, being an alternative to more complex and expensive measures, such as positron emission tomography imaging or cerebrospinal fluid measurement.
Product Description
Cat No. of Pruducts
GMP-h-Aβ42-Ag01
Product Name
Recombinant human Human Aβ42 Protein
Target
beta-amyloid 42
Alias of Target/Biomarker
Expression platform
E.coli
Isotypes
Recombinant Antigen
Bioactivity validation
beta-amyloid 42 (Aβ42) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Aβ42 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation
Tag
His
Products description
Recombinant human Human Aβ42 Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
positive control,
ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -96℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Previous slide
Next slide
Cat No. of Pruducts
GMP-h-Aβ42-Ab01,GMP-h-Aβ42-Ab02
Product Name
Anti-human Human Aβ42 mouse monoclonal antibody (mAb)
Target
beta-amyloid 42
Alias of Target/Biomarker
AAA, ABETA, ABPP, AD1I, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4, APP
Expression platform
Hybridoma
Isotypes
Mouse IgG
Bioactivity validation
Human beta-amyloid 42 (Aβ42) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other beta-amyloid 42 (Aβ42) antibodies in Aβ42 level test of Neurodegenerative diseases (Alzheimer Disease(AD)) and related syndrome evaluation.
Tag
mFc
Products description
Anti-human Human Aβ42 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other beta-amyloid 42 (Aβ42) antibodies.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -97℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
